Insiders · ALXN

Andreas Rummelt

Director at Alexion Pharmaceuticals, Inc. (ALXN)

Andreas Rummelt has filed 2 insider reports with the SEC since May 2021, as director at Alexion Pharmaceuticals, Inc. (ALXN). The latest filing, on July 23, 2021, reports sale back to the company at Alexion Pharmaceuticals, Inc. (ALXN).

Filings
2
Companies
1
Bought on market
None
Sold on market
None

Companies where Andreas Rummelt is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Alexion Pharmaceuticals, Inc. logo
ALXN
Alexion Pharmaceuticals, Inc.
Director0Jul 23, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Andreas Rummelt with

Questions about Andreas Rummelt

What is Andreas Rummelt's role at Alexion Pharmaceuticals, Inc.?
Andreas Rummelt reports to the SEC as director at Alexion Pharmaceuticals, Inc. (ALXN), according to the latest filing on July 23, 2021.
Has Andreas Rummelt bought or sold stock recently?
No open-market purchases or sales by Andreas Rummelt are on file. The filings report sale back to the company and grant or award.
How do I get alerts when Andreas Rummelt files?
Follow Andreas Rummelt on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Andreas Rummelt (SEC CIK 0001484986). Totals count each trade once, skipping amendments whose original is on file, from May 24, 2021 on. View on SEC EDGAR · Get this as JSON